India’s healthcare regulatory framework is evolving to match global pharmaceutical standards. Recently, the government proposed a significant amendment related to the testing process of medicines derived from human plasma. The proposal aims to remove the requirement for repeated virus testing on finished plasma-based medicines, as the raw plasma used in manufacturing is already rigorously screened for infections before production begins.
This proposed change is expected to streamline the regulatory process while maintaining the highest safety standards for patients who rely on these critical therapies.
Understanding Plasma-Derived Medicines
Plasma is the liquid component of human blood that contains essential proteins, antibodies, and clotting factors. Through specialized manufacturing processes known as plasma fractionation, these proteins are separated and transformed into life-saving medicines.
Common plasma-derived medicinal products include:
-
Albumin
-
Intravenous Immunoglobulin (IVIG)
-
Clotting Factors such as Factor VIII and Factor IX
These medicines are widely used in hospitals to treat a variety of serious medical conditions such as:
-
Immune system disorders
-
Severe infections
-
Burn injuries
-
Trauma cases
-
Bleeding disorders like haemophilia
Because of their life-saving role, maintaining strict safety standards during manufacturing and testing is essential.
Current Testing System in India
Under the existing drug regulations, plasma collected from blood donors undergoes multiple testing stages before being used to manufacture medicines.
The typical process involves:
-
Collection of plasma from blood donors
-
Pooling of plasma from multiple donors
-
Screening of pooled plasma for viruses
-
Manufacturing of plasma-derived medicines
-
Testing the finished products again for the same viruses
The viral tests generally look for markers of serious infections such as:
-
HIV antibodies
-
Hepatitis B surface antigen
-
Hepatitis C virus RNA
While this system ensures a high level of safety, health officials believe that repeating the same tests at the final product stage may be unnecessary when the raw plasma has already been thoroughly screened.
Proposed Change in Drug Rules
The government has proposed amending the Drugs Rules, 1945, which regulate blood-derived medicinal products in India.
The key proposal is:
To eliminate the second round of viral testing performed on finished plasma-derived medicines.
According to officials, this step will align India’s regulatory practices with internationally accepted pharmacopoeia standards followed in several advanced healthcare systems.
Global guidelines already require strict testing of pooled plasma before it is used for manufacturing. Only plasma that tests negative for major viral infections is allowed to proceed for fractionation.
Therefore, authorities believe that repeating the same viral tests on finished products results in duplication without adding significant safety benefits.
International Standards and Practices
Many countries follow international pharmacopoeia guidelines for plasma-derived medicinal products. These standards focus on comprehensive screening at the plasma stage rather than duplicate testing later.
Under global guidelines:
-
Pooled plasma must be tested for viral markers before fractionation.
-
Only infection-free plasma can be used for manufacturing.
-
The production process includes viral inactivation and removal steps that eliminate potential pathogens.
These processes ensure that the final medicines are safe for clinical use.
By adopting similar practices, India aims to harmonize its regulatory system with international pharmaceutical standards.
Safety Measures Already in Place
Even if duplicate testing is removed, multiple layers of safety checks will remain in the production of plasma-derived medicines.
Key safety measures include:
1. Donor Screening
Blood donors are carefully screened through health questionnaires and medical checks to identify potential risks.
2. Infection Testing
Donated plasma is tested for infections such as:
-
HIV
-
Hepatitis B
-
Hepatitis C
-
Malaria
-
Syphilis
Only plasma that clears these tests is used for further processing.
3. Viral Inactivation During Manufacturing
The plasma fractionation process includes advanced viral inactivation techniques that eliminate possible pathogens.
These steps ensure that the final medicinal products remain safe for patient use.
Importance of Plasma Fractionation
Blood donation centers often collect more plasma than is required for immediate patient needs. This surplus plasma can be supplied to specialized fractionation facilities where valuable proteins are extracted.
Plasma fractionation allows the healthcare system to convert donated plasma into medicines that help thousands of patients suffering from chronic and life-threatening diseases.
These medicines are particularly crucial for:
-
Patients with immune deficiencies
-
Individuals suffering from rare bleeding disorders
-
People requiring critical care treatment
Because of the complex manufacturing process, ensuring regulatory efficiency is essential to maintain consistent supply.
Benefits of the Proposed Amendment
If implemented, the proposed regulatory change may offer several advantages:
Improved Regulatory Efficiency
Removing unnecessary duplicate testing could streamline the approval and manufacturing process.
Faster Availability of Medicines
Simplifying testing procedures may reduce delays in production and distribution.
Alignment with Global Standards
Harmonizing regulations with international pharmacopoeia practices can strengthen India’s pharmaceutical regulatory framework.
Reduced Manufacturing Costs
Eliminating redundant testing may help reduce production costs without compromising safety.
Consultation with Experts and Stakeholders
Before implementing the amendment, the government consulted technical experts and regulatory authorities. The proposal was reviewed by the Drugs Technical Advisory Board, which plays a crucial role in advising the government on pharmaceutical regulations.
A draft notification has been issued inviting public comments and stakeholder feedback on the proposed amendment.
Industry experts, healthcare professionals, and other stakeholders have been given 30 days to submit their suggestions before the final rules are notified.
The Future of Plasma-Derived Medicines in India
India’s healthcare system is continuously evolving to ensure both safety and efficiency in the pharmaceutical sector. The proposed amendment reflects an effort to modernize regulations while maintaining strict patient safety standards.
By focusing on robust screening of donated plasma and advanced manufacturing safeguards, authorities aim to ensure that plasma-derived medicines remain safe, effective, and widely available to patients who need them.
As healthcare technologies and regulatory frameworks continue to improve, such policy updates can play an important role in strengthening the country’s pharmaceutical ecosystem and improving access to life-saving therapies.